Replies to post #588468 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

People aren’t talking more about the lawsuit. It just so happened yesterday the Plaintiff’s firm added a whistleblower attorney. That blip does not mean the patients or science are secondary. No one is investing in NWBO based upon the lawsuit against market makers. Market makers might be chastened at some point however. People invest in NWBO because the Dendritic Cell technology, and combinations therewith, increase the chances at long term survival, and for some, lifetime remission.

[Doc logic]

HappyLibrarian,

Anyone viewing this as a litigation opportunity or suggesting that I have has not looked at the numbers very well that sees a $.51 stock getting a potential payout of $1-$2/share in a few years depending on any further dilution and other factors. That will pale in comparison to the value added from MAA/BLA, manufacturing or partnership news in the mean time. This is not about “the company” making litigation “a problem” it’s about NWBO making this lawsuit an issue for good reason. Any potential investor doing even minimal due diligence will look right past the lawsuit as reason for investing and take a peek at the JAMA Oncology abstract. They will also recognize how long everything is taking to turn research into clinical practice due to manufacturing hurdles for mass production and release of a personalized product being cleared slowly but being cleared cleanly. Best wishes.

[biosectinvestor]

Except that we disagree on what that is about and what it means. But I appreciate that we agree that the primary narrative of the company is not that “we’re going to make a lot of money from litigation.”